Abstract
Huntington’s disease (HD) is a paradigm of a genetic neurodegenerative disorder characterized by the expansion of CAG repeats in the HTT gene. This extensive review investigates the molecular complexities of HD by highlighting the pathogenic mechanisms initiated by the mutant huntingtin protein. Adverse outcomes of HD include mitochondrial dysfunction, compromised protein clearance, and disruption of intracellular signaling, consequently contributing to the gradual deterioration of neurons. Numerous therapeutic strategies, particularly precision medicine, are currently used for HD management. Antisense oligonucleotides, such as Tominersen, play a leading role in targeting and modulating the expression of mutant huntingtin. Despite the promise of these therapies, challenges persist, particularly in improving delivery systems and the necessity for long-term safety assessments. Considering the future landscape, the review delineates promising directions for HD research and treatment. Innovations such as Clustered regularly interspaced short palindromic repeats associated system therapies (CRISPR)-based genome editing and emerging neuroprotective approaches present unprecedented opportunities for intervention. Collaborative interdisciplinary endeavors and a more insightful understanding of HD pathogenesis are on the verge of reshaping the therapeutic landscape. As we navigate the intricate landscape of HD, this review serves as a guide for unraveling the intricacies of this disease and progressing toward transformative treatments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this manuscript.
References
Adachi N, Numakawa T, Richards M, Nakajima S, Kunugi H (2014) New insight in expression, transport, and secretion of brain-derived neurotrophic factor: implications in brain-related diseases. World J Biol Chem 5(4):409–428. https://doi.org/10.4331/wjbc.v5.i4.409
Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67(4):657–685. https://doi.org/10.1128/MMBR.67.4.657-685.2003
Agustín-Pavón C, Mielcarek M, Garriga-Canut M, Isalan M (2016) Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mole Neurodegener. https://doi.org/10.1186/s13024-016-0128-x
Alkanli SS, Alkanli N, Ay A, Albeniz I (2023) CRISPR/Cas9 mediated therapeutic approach in Huntington’s disease. Mol Neurobiol 60(3):1486–1498. https://doi.org/10.1007/s12035-022-03150-5
Alpay M, Koroshetz WJ (2006) Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics 47(1):70–72. https://doi.org/10.1176/appi.psy.47.1.70
Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Chakole RD, Nemade LS, Kale NK, Borah S, Deokar SS (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis-an updated review. Mitochondrion Jul 71:83–92. https://doi.org/10.1016/j.mito.2023.05.007
Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389(6653):856–860. https://doi.org/10.1038/39885
Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A, Read A, MacDonald ME (1994) Structure and expression of the Huntington’s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell Genetics 20(1):27–38. https://doi.org/10.1007/BF02257483
Anderson KE, Stevenson M, Varghese R, Hebron ML, Koppel E, McCartin M, Kuprewicz R, Matar S, Ferrante D, Moussa C (2022) Alteration of autophagy and glial activity in nilotinib-treated Huntington’s disease patients. Metabolites 12(12):1225. https://doi.org/10.3390/metabo12121225
Andhale R, Shrivastava D (2022) Huntington’s disease: a clinical review. Cureus. https://doi.org/10.7759/cureus.28484
Armstrong MJ, Miyasaki JM, American Academy of Neurology (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 79(6):597–603. https://doi.org/10.1212/WNL.0b013e318263c443
Bachoud-Lévi A-C, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D (2019) International guidelines for the treatment of Huntington’s disease. Front Neurol 10:710. https://doi.org/10.3389/fneur.2019.00710
Badadhe S, Bhosale V, Kulkarni P, Gangurde H (2024) Huntington disease: brief overview. Innov J Med Healthcare Res. https://doi.org/10.1038/nrdp.2015.5
Baig SS, Strong M, Quarrell OW (2016) The global prevalence of Huntington’s disease: a systematic review and discussion. Neurodegener Dis Manag 6(4):331–343. https://doi.org/10.2217/nmt-2016-0008
Baquet ZC, Gorski JA, Jones KR (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24:4250–4258. https://doi.org/10.1523/JNEUROSCI.3920-03.2004
Barr A, Fischer J, Roller W, Spunt A, Singhal A (1988) Serum haloperidol concentration and choreiform movements in Huntington’s disease. Neurology 38:84–84. https://doi.org/10.1212/wnl.38.1.84
Bartley OJ, Lelos MJ, Gray WP, Rosser AE (2021) Do foetal transplant studies continue to be justified in Huntington’s disease? Neuronal Signaling 5:NS20210019. https://doi.org/10.1042/NS20210019
Belgrad J, Khvorova A (2024) More than 185 CAG repeats: a point of no return in Huntington’s disease biology. Brain 8:awae105. https://doi.org/10.1093/brain/awae105
Berardelli A, Noth J, Thompson PD, Bollen EL, Currà A, Deuschl G, Gert Van Dijk J, Töpper R, Schwarz M, Roos RA (1999) Pathophysiology of chorea and bradykinesia in Huntington’s disease. Mov Disord 14:398–403. https://doi.org/10.1002/1531-8257(199905)14:3%3c398::aid-mds1003%3e3.0.co;2-f
Bhat AA, Gupta G, Afzal O, Kazmi I, Al-Abbasi FA, Altamimi ASA, Almalki WH, Alzarea SI, Singh SK, Dua K (2023) Neuropharmacological effect of risperidone: from chemistry to medicine. Chem Biol Interactions. https://doi.org/10.1016/j.cbi.2022.110296
Binvignat O, Olloquequi J (2020) Excitotoxicity as a target against neurodegenerative processes. Curr Pharm Des 26(12):1251–1262. https://doi.org/10.2174/1381612826666200113162641
Bogelman G, Hirschmann S, Modai I (2001) Olanzapine and Huntington’s disease. J Clin Psychopharmacol 21:245–246. https://doi.org/10.1097/00004714-200104000-00023
Bonelli RM, Niederwieser G (2002) Quetiapine in Huntington’s disease: a first case report. J Neurol 249:1114–1115. https://doi.org/10.1007/s00415-002-0741-1
Bonelli RM, Mahnert FA, Niederwieser G (2002) Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol 25:263–265. https://doi.org/10.1097/00002826-200209000-00007
Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A (1994) Clozapine in Huntington’s chorea. Neurology 44:821–821. https://doi.org/10.1212/wnl.44.5.821
Brown CS, Markowitz JS, Moore TR, Parker NG (1999) Atypical antipsychotics: part II adverse effects, drug interactions, and costs. Ann Pharmacother 33:210–217. https://doi.org/10.1345/aph.17216
Browne SE, Beal MF (2004) The energetics of Huntington’s disease. Neurochem Res 29:531–546. https://doi.org/10.1023/b:nere.0000014824.04728.dd
Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB (2009) Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 24:126–129. https://doi.org/10.1002/mds.22376
Burgunder J-M, Guttman M, Perlman S, Goodman N, Van Kammen DP, Goodman L (2011) An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr. https://doi.org/10.1371/currents.RRN1260
Byun S, Lee M, Kim M (2022) Gene therapy for Huntington’s disease: the final strategy for a cure? Journal of Movement Disorders 15(1):15. https://doi.org/10.14802/jmd.21006
Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979) The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317–320. https://doi.org/10.1176/ajp.136.3.317
Cao LX, Yin JH, Du G, Yang Q, Huang Y (2024) Identifying and verifying Huntington’s disease subtypes: clinical features, neuroimaging, and cytokine changes. Brain Behav 14(3):e3469. https://doi.org/10.1002/brb3.3469
Caron NS, Banos R, Yanick C, Aly AE, Byrne LM, Smith ED, Xie Y, Smith SEP, Potluri N, Findlay Black H, Casal L, Ko S, Cheung D, Kim H, Seong IS, Wild EJ, Song J-J, Hayden MR, Southwell AL (2021) Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease. J Neurosci 41(4):780–796. https://doi.org/10.1523/JNEUROSCI.1865-20.2020
Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci 24:182–188. https://doi.org/10.1016/s0166-2236(00)01721-5
Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci 6:919–930. https://doi.org/10.1038/nrn1806
Chen C-M, Wu Y-R, Cheng M-L, Liu J-L, Lee Y-M, Lee P-W, Soong B-W, Chiu DT-Y (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun 359:335–340. https://doi.org/10.1016/j.bbrc.2007.05.093
Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34:1487–1504. https://doi.org/10.1016/j.clinthera.2012.06.010
Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, Squitieri F, Silani V (2007) Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington’s disease patients. Am J Med Genet B Neuropsychiatr Genet 144:574–577. https://doi.org/10.1002/ajmg.b.30501
Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, Squitieri F, Silani V (2009) Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatric Dis Treat. https://doi.org/10.2147/ndt.s12160236
Cicchetti F, Prensa LA, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease. Brain Res Rev 34:80–101. https://doi.org/10.1016/s0165-0173(00)00039-4
Citrome L (2017) Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 71:e13030. https://doi.org/10.1111/ijcp.13030
Claassen DO, Ayyagari R, García-Horton V, Zhang S, Leo S (2023) Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. Ment Health Clin 13(5):207–216. https://doi.org/10.9740/mhc.2023.10.207
Coppen EM, Roos RA (2017) Current pharmacological approaches to reduce chorea in Huntington’s disease. Drugs 77:29–46. https://doi.org/10.1007/s40265-016-0670-4
Croce KR, Yamamoto A (2019) A role for autophagy in Huntington’s disease. Neurobiol Dis 122:16–22. https://doi.org/10.1016/j.nbd.2018.08.010
Crowell V, Houghton R, Tomar A, Fernandes T, Squitieri F (2021) Modeling manifest Huntington’s disease prevalence using diagnosed incidence and survival time. Neuroepidemiology 55:361–368. https://doi.org/10.1159/000516767
D’Egidio F, Castelli V, Cimini A, D’angelo M (2023) Cell rearrangement and oxidant/antioxidant imbalance in huntington’s disease. Antioxidants 12:571. https://doi.org/10.3390/antiox12030571
Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M (2018) Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases. Front Neurosci 12:75. https://doi.org/10.3389/fnins.2018.00075
Dai Y, Wang H, Lian A, Li J, Zhao G, Hu S, Li B (2023) A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction. Mitochondrion 70:8–19. https://doi.org/10.1016/j.mito.2023.03.001
Dallocchio C, Buffa C, Tinelli C, Mazzarello P (1999) Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 19:101–103. https://doi.org/10.1097/00004714-199902000-00020
Dash D, Mestre TA (2020) Therapeutic update on Huntington’s disease: symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics 17:1645–1659. https://doi.org/10.1007/s13311-020-00891-w
De La C, Hwang J (2021) On the hunt for a cure: a guide to Huntington disease. JAAPA 34(4):26–31
De Guire SM, Ruggeri FS, Fares MB, Chiki A, Cendrowska U, Dietler G, Lashuel HA (2018) N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting. J Biol Chem 293(48):18540–18558. https://doi.org/10.1074/jbc.RA118.004621
De Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM (2004) Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord 19:1516–1518. https://doi.org/10.1002/mds.20235
De Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt Å (2011) Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049–1057. https://doi.org/10.1016/S1474-4422(11)70233-2
Dellosso L, Bonelli C, Nardi B, Giovannoni F, Pronestì C, Cremone IM, Amatori G, Pini S, Carpita B (2024) Rethinking clozapine: lights and shadows of a revolutionary drug. Brain Sci 14:103. https://doi.org/10.3390/brainsci14010103
Denis HL, David LS, Cicchetti F (2019) Antibody-based therapies for Huntington’s disease: current status and future directions. Neurobiol Dis 132:104569. https://doi.org/10.1016/j.nbd.2019.104569
Devadiga SJ, Bharate SS (2022) Recent developments in the management of Huntington’s disease. Bioorg Chem 120(105642):105642. https://doi.org/10.1016/j.bioorg.2022.105642
Difiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel J-P, Carraway R, Reeves SA (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14:1075–1081. https://doi.org/10.1016/0896-6273(95)90346-1
Dipple HC (1999) The use of olanzapine for movement disorder in Huntington’s disease: a first case report. J Neurol Neurosurg Psychiatry 67:123–124. https://doi.org/10.1136/jnnp.67.1.123
Donaldson J, Powell S, Rickards N, Holmans P, Jones L (2021) What is the pathogenic CAG expansion length in Huntington’s disease? J Huntington’s Dis 10(1):175–202. https://doi.org/10.3233/JHD-200445
Drew CJ, Sharouf F, Randell E, Brookes-Howell L, Smallman K, Sewell B, Burrell A, Kirby N, Mills L, Precious S (2021) Protocol for an open label: phase I trial within a cohort of foetal cell transplants in people with Huntington’s disease. Brain Commun 3:fcaa230. https://doi.org/10.1093/braincomms/fcaa230
Duff K, Beglinger LJ, O’rourke ME, Nopoulos P, Paulson HL, Paulsen JS (2008) Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry 20:1–3. https://doi.org/10.1080/10401230701844802
Ehrlich ME (2012) Huntington’s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9:270–284. https://doi.org/10.1007/s13311-012-0112-2
Eje O, Ogbonna C, Onoyima C, Nduka F (2023) Huntington disease: mechanism of pathogenesis and recent developments in its therapeutic strategies: a review. J Chem Rev 5(2):129–142. https://doi.org/10.22034/jcr.2023.362508.1194
Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T (2019) CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington’s disease mouse model. Mol Ther Nucleic Acids 17:829–839. https://doi.org/10.1016/j.omtn.2019.07.009
Erdemoglu AK, Boratav C (2002) Risperidone in chorea and psychosis of Huntington’s disease. European J Neurol 9(2):182–183. https://doi.org/10.1046/j.1468-1331.2002.0354e.x
Estrada-Sánchez AM, Rebec GV, Galvan L (2023) Editorial: new insight into Huntington’s disease: from neuropathology to possible therapeutic targets. Front Neurosci 17:1138712. https://doi.org/10.3389/fnins.2023.1138712
Evers MM, Konstantinova P (2020) AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins. Expert Opin Biol Ther 20(10):1121–1124. https://doi.org/10.1080/14712598.2020.1792880
Fan H-C, Chi C-S, Lee Y-J, Tsai J-D, Lin S-Z, Harn H-J (2018) The role of gene editing in neurodegenerative diseases. Cell Transplant 27(3):364–378. https://doi.org/10.1177/0963689717753378
Fão L, Rego AC (2021) Mitochondrial and redox-based therapeutic strategies in Huntington’s disease. Antioxid Redox Signal 34(8):650–673. https://doi.org/10.1089/ars.2019.8004
Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Current and possible future therapeutic options for Huntington’s disease. J Central Nervous Syst Disease 14:11795735221092516. https://doi.org/10.1177/11795735221092517
Fernandez HH, Friedman JH, Grace J, Beason-Hazen S (2000) Donepezil for Huntington’s disease. Mov Disord 15(1):173–176. https://doi.org/10.1002/1531-8257(200001)15:1%3c173::aid-mds1032%3e3.0.co;2-t
Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722–747
Fodale V, Pintauro R, Daldin M, Altobelli R, Spiezia MC, Bisbocci M, Macdonald D, Bresciani A (2020) Analysis of mutant and total huntingtin expression in Huntington’s disease murine models. Sci Rep 10(1):22137. https://doi.org/10.1038/s41598-020-78790-5
Frank S (2009) Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 9(1):62. https://doi.org/10.1186/1471-2377-9-62
Frank S (2014) Treatment of Huntington’s disease. Neurotherapeutics 11:153–160. https://doi.org/10.1007/s13311-013-0244-z
Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O’Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Christopher E (2016) Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial: A randomized clinical trial. JAMA 316(1):40–50. https://doi.org/10.1001/jama.2016.8655
Gafni J, Ellerby LM (2002) Calpain activation in Huntington’s disease. J Neurosci 22(12):4842–4849. https://doi.org/10.1523/jneurosci.22-12-04842.2002
Galindo M, Da Silva GV, Lopes I, De Araújo Ramos VE, De Oliveira T, Bueno G (2023) Unraveling huntington’s disease: concepts, treatments and health policy challenges. Revista Ibero-Americana De Humanidades, Ciências e Educação 9(11):4010–4021. https://doi.org/10.51891/rease.v9i11.12684
Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-Mohapel J (2019) Depression in neurodegenerative diseases: common mechanisms and current treatment options. Neurosci Biobehav Rev 102:56–84. https://doi.org/10.1016/j.neubiorev.2019.04.002
García-González X, Cubo E, Simón-Vicente L, Mariscal N, Alcaraz R, Aguado L, Rivadeneyra-Posadas J, Sanz-Solas A, Saiz-Rodríguez M (2023) Pharmacogenetics in the treatment of Huntington’s disease: review and future perspectives. J Pers Med. https://doi.org/10.3390/jpm13030385
Garrett M, Soares-Da-Silva P (1992) Increased cerebrospinal fluid dopamine and 3, 4-dihydroxyphenylacetic acid levels in Huntington’s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 58(1):101–106
Garriga-Canut M, Agustín-Pavón C, Herrmann F, Sánchez A, Dierssen M, Fillat C, Isalan M (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109(45):E3136–E3145. https://doi.org/10.1073/pnas.1206506109
Gaudet ID, Xu H, Gordon E, Cannestro GA, Lu ML, Wei J (2024) Elevated SLC7A2 expression is associated with an abnormal neuroinflammatory response and nitrosative stress in Huntington’s disease. J Neuroinflammation 21(1):59. https://doi.org/10.1186/s12974-024-03038-2
Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127–138. https://doi.org/10.1016/j.cell.2004.06.018
Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 27(11):2803–2820. https://doi.org/10.1111/j.1460-9568.2008.06310.x
Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR (2020) Patient-reported impact of symptoms in Huntington disease: PRISM-HD: PRISM-HD. Neurology 94(19):e2045–e2053. https://doi.org/10.1212/WNL.0000000000008906
Goetz C, Koller W, Poewe W, Rascol O, Sampaio C, Brin M, Lees AJ, Lewitt P, Lozano A, Mizuno Y (2002) Amantadine and other antiglutamate agents. Mov Disord 17:S13–S22. https://doi.org/10.1002/mds.5557
Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K (2024) Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review. Tremor Hyperkinetic Mov. https://doi.org/10.5334/tohm.842
Goodliffe J, Rubakovic A, Chang W, Pathak D, Luebke J (2020) Structural and functional features of medium spiny neurons in the BACHDΔN17 mouse model of Huntington’s Disease. PLoS ONE 15(6):e0234394. https://doi.org/10.1371/journal.pone.0234394
Gordon M F, Hauser R A, Barkay H, Fernandez HH, Factor SA, Jimenez-Shahed J, Anderson KE (2022) Effects of long-term deutetrabenazine treatment in patients with tardive dyskinesia and underlying psychiatric or mood disorders (P9–11.002). https://doi.org/10.1212/WNL.98.18_supplement.1791
Groenewald FCE, Kok RM (2024) Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults. Int J Geriatr Psychiatry 39(1):e6051. https://doi.org/10.1002/gps.6051
Group HS (2003) Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology 61(11):1551–1556. https://doi.org/10.1212/01.wnl.0000096019.71649.2b
Group HS (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66(3):366–372. https://doi.org/10.1212/01.wnl.0000198586.85250.13
Groves M, van Duijn E, Anderson K, Craufurd D, Edmondson MC, Goodman N, van Kammen DP, Goodman L (2011) An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington’s disease. PLoS Curr 3:RRN1259. https://doi.org/10.1371/currents.RRN1259
Gunn S, Dale M, Ovaska-Stafford N, Maltby J (2023) Mental health symptoms among those affected by Huntington’s disease: a cross-sectional study. Brain and Behavior 13(4):e2954. https://doi.org/10.1002/brb3.2954
Gupta H, Perkins W, Stark C, Kikkeri S, Kakazu J, Kaye A, Kaye A (2022) deutetrabenazine for the treatment of chorea associated with Huntington’s disease. Health Psychol Res 10(3):36040. https://doi.org/10.52965/001c.36040
Gupta D, Bhardwaj A, Ankur A, Ambaliya C (2023) Psychosis and its linear outcomes: Huntington’s disease. Ann Indian Psychiatry 7(2):170–172. https://doi.org/10.4103/aip.aip_195_22
Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM (1998) The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J Neurosci 18(19):7674–7686. https://doi.org/10.1523/jneurosci.18-19-07674.1998
Han JY, Seo J, Choi Y, Im W, Ban J-J, Sung J-J (2023) CRISPR-Cas9 mediated genome editing of Huntington’s disease neurospheres. Mol Biol Rep 50(3):2127–2136. https://doi.org/10.1007/s11033-022-08175-6
Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28(8):425–433. https://doi.org/10.1016/S0968-0004(03)00168-3
Hassan W, Noreen H, Rehman S, Kamal MA, da Rocha JBT (2022) Association of oxidative stress with neurological disorders. Curr Neuropharmacol 20(6):1046–1072. https://doi.org/10.2174/1570159X19666211111141246
Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P (2009) Tetrabenazine. Nat Rev Drug Discov 8(1):17–18. https://doi.org/10.1038/nrd2784
Heinz A, Nabariya DK, Krauß S (2023) Huntington’s disease and neurodegeneration. Handbook of neurotoxicity. Springer, Cham, pp 1765–1787. https://doi.org/10.1007/978-3-031-15080-7_226
Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 29(10):3200–3205. https://doi.org/10.1523/JNEUROSCI.5599-08.2009
Heo Y-A, Scott LJ (2017) Deutetrabenazine: a review in chorea associated with Huntington’s disease. Drugs 77(17):1857–1864. https://doi.org/10.1007/s40265-017-0831-0
Hergert DC, Sanchez-Ramos J, Cimino CR (2020) Awareness of chorea in Huntington’s disease. J Huntington’s Dis 9(1):99–103. https://doi.org/10.3233/JHD-190381
Hersch S, Claassen D, Edmondson M, Wild E, Guerciolini R, Panzara M (2017) Multicenter, randomized, double-blind, placebo-controlled phase 1b/2a studies of WVE-120101 and WVE-120102 in patients with Huntington’s disease (P2. 006). AAN Enterp. https://doi.org/10.1212/wnl.88.16_supplement.p2.006
Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA (1990) Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 9(8):2459–2464. https://doi.org/10.1002/j.1460-2075.1990.tb07423.x
Hoffner G, Djian P (2002) Protein aggregation in Huntington’s disease. Biochimie 84(4):273–278. https://doi.org/10.1016/s0300-9084(02)01398-6
Hong EP, MacDonald ME, Wheeler VC, Jones L, Holmans P, Orth M, Monckton DG, Long JD, Kwak S, Gusella JF, Lee J-M (2021) Huntington’s disease pathogenesis: two sequential components. J Huntington’s Dis 10(1):35–51. https://doi.org/10.3233/JHD-200427
Hoschek F, Natan J, Wagner M, Sathasivam K, Abdelmoez A, von Einem B, Bates GP, Landwehrmeyer GB, Neueder A (2024) Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues. Mol Med 30(1):36. https://doi.org/10.1186/s10020-024-00801-2
Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A (2007) Patients with Huntington’s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 29(4):365–376. https://doi.org/10.1080/13803390600718958
Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31(9):827–832. https://doi.org/10.1038/nbt.2647
Investigators H (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord 28(10):1407–1415. https://doi.org/10.1002/mds.25362
Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM (2003) Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 15(1):33–48. https://doi.org/10.1023/a:1023228626309
Jana S, Giri B, Das S, Manna A, Mandal SC, Ranjan JN (2024) Azadiradione up-regulates the expression of parvalbumin and BDNF via Ube3a. Gene 897:148081. https://doi.org/10.1016/j.gene.2023.148081
Jing L, Cheng S, Pan Y, Liu Q, Yang W, Li S, Li X-J (2021) Accumulation of endogenous mutant huntingtin in astrocytes exacerbates neuropathology of Huntington disease in mice. Mol Neurobiol 58(10):5112–5126. https://doi.org/10.1007/s12035-021-02451-5
Kaczmarek JC, Kowalski PS, Anderson DG (2017) Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med 9:1–16. https://doi.org/10.1186/s13073-017-0450-0
Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V (2016) Tetrabenazine: spotlight on drug review. Ann Neurosci 23(3):176–185. https://doi.org/10.1159/000449184
Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington’s disease and spinocerebellar ataxia. Hum Mol Genet 25(R1):R53-64. https://doi.org/10.1093/hmg/ddv442
Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington’s disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 98(22):12784–12789. https://doi.org/10.1073/pnas.221451398
Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet 19(20):3919–3935. https://doi.org/10.1093/hmg/ddq306
Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J (2021) New avenues for the treatment of Huntington’s disease. Int J Mol Sci 22(16):8363. https://doi.org/10.3390/ijms22168363
Kish SJ, Shannak K, Hornykiewicz O (1987) Elevated serotonin and reduced dopamine in subregionally divided Huntington’s disease striatum. Ann Neurol 22(3):386–389. https://doi.org/10.1002/ana.410220318
Koch ET, Raymond LA (2019) Dysfunctional striatal dopamine signaling in Huntington’s disease. J Neurosci Res 97(12):1636–1654. https://doi.org/10.1002/jnr.24495
Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL (2017) CRISPR-Cas9 mediated gene-silencing of the mutant huntingtin gene in an in vitro model of Huntington’s disease. Int J Mol Sci 18(4):754. https://doi.org/10.3390/ijms18040754
Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S (2011) Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 1:CD006626. https://doi.org/10.1002/14651858.CD006626.pub2
Krzysztoń-Russjan J, Zielonka D, Jackiewicz J, Kuśmirek S, Bubko I, Klimberg A, Marcinkowski JT, Anuszewska EL (2013) A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington’s disease: looking for biomarkers. J Bioenerg Biomembr 45(1–2):71–85. https://doi.org/10.1007/s10863-012-9479-3
Kumar A, Ratan RR (2016) Oxidative stress and Huntington’s disease: the good, the bad, and the ugly. J Huntington’s Dis 5(3):217–237. https://doi.org/10.3233/jhd-160205
Kumar P Jr (2017) [P2–081]: Possible involvement of calcium channels in neuroprotective mechanism of fenofibrate against 3-nitropropionic acid-induced Huntington’s disease in rats. Alzheimer’s Dementia 13(7S_Part_12):P637–P637. https://doi.org/10.1016/j.jalz.2017.06.730
Kumar A, Kumar V, Singh K, Kumar S, Kim Y-S, Lee Y-M, Kim J-J (2020) Therapeutic advances for Huntington’s disease. Brain Sci 10(1):43. https://doi.org/10.3390/brainsci10010043
Kumar R, Claassen DO, Mongan A, Hoehn B, Lin P, Cahir-Mcfarland E, Taylor L, Chandra P, Yednock T, Kroon H-A (2022) J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD). J Neurol Neurosurg Psychiatry 2022(93):A96–A97. https://doi.org/10.1136/jnnp-2022-ehdn.258
Kumar D, Hasan GM, Islam A, Hassan MI (2023a) Therapeutic targeting of Huntington’s disease: molecular and clinical approaches. Biochem Biophys Res Commun 655:18–24. https://doi.org/10.1016/j.bbrc.2023.02.075
Kumar R, Claassen D, Mongan A, Hoehn B, Lin P, Cahir-Mcfarland E, Guo C, Volman V, Taylor L, Chandra P, Yednock T, Kroon H-A (2023b) A phase 2 open-label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD) (S32.009). Neurology 100(17_supplement_2):3366. https://doi.org/10.1212/WNL.0000000000203217
LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M (2017) Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial. Neurol Neuroimmunol Neuroinflamm 4(4):e367. https://doi.org/10.1212/nxi.0000000000000367
Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15(7):5297–5307. https://doi.org/10.1523/jneurosci.15-07-05297.1995
Landwehrmeyer GB, Dubois B, de Yébenes JG, Kremer B, Gaus W, Kraus PH, Przuntek H, Dib M, Doble A, Fischer W, Ludolph AC, European Huntington’s Disease Initiative Study Group (2007) Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol 62(3):262–272. https://doi.org/10.1002/ana.21181
Li S-H, Li X-J (2004) Huntingtin-protein interactions and the pathogenesis of Huntington’s disease. Trends in Genetics: TIG 20(3):146–154. https://doi.org/10.1016/j.tig.2004.01.008
Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1(6):361–370. https://doi.org/10.1016/j.cmet.2005.05.004
Lunkes A, Lindenberg KS, Ben-Haïem L, Weber C, Devys D, Landwehrmeyer GB, Mandel J-L, Trottier Y (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10(2):259–269. https://doi.org/10.1016/s1097-2765(02)00602-0
Maiese K (2023) The metabolic basis for nervous system dysfunction in Alzheimer’s disease, Parkinson’s Disease, and Huntington’s disease. Curr Neurovasc Res 20(3):314–333. https://doi.org/10.2174/1567202620666230721122957
Martinez-Vicente M (2015) Autophagy in neurodegenerative diseases: from pathogenic dysfunction to therapeutic modulation. Semin Cell Dev Biol 40:115–126. https://doi.org/10.1016/j.semcdb.2015.03.005
Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, de Vries R, Arias E, Harris S, Sulzer D, Cuervo AM (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat Neurosci 13(5):567–576. https://doi.org/10.1038/nn.2528
Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin lowering strategies. Int J Mol Sci 21(6):2146. https://doi.org/10.3390/ijms21062146
Massey TH, McLauchlan DJ (2024) Huntington’s disease: a clinical primer for acute and general physicians. Clin Med (lond) 6:100200. https://doi.org/10.1016/j.clinme.2024.100200
Maucksch C, Vazey EM, Gordon RJ, Connor B (2013) Stem cell-based therapy for Huntington’s disease. J Cell Biochem 114(4):754–763. https://doi.org/10.1002/jcb.24432
Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC (2014) Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 13:1163–1191
McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Comfort N, Wang B, Amacker J, Thankamony S, Salzman DW, Cudkowicz M, Graham DL, Miller TM (2018) Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Investig 128(8):3558–3567. https://doi.org/10.1172/JCI99081
McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, Zhou J, Schlegel V, Sanwald Ducray P, Hawellek DJ, Dorn J, Simillion C, Lindemann M, Wheelock V, Durr A, Anderson KE, Long JD, Wild EJ, GENERATION HD1 Investigators (2023) Tominersen in adults with manifest Huntington’s disease. New England J Med 389(23):2203–2205. https://doi.org/10.1056/NEJMc2300400
Mehanna R, Jankovic J (2024) Systemic symptoms in huntington’s disease: a comprehensive review. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.14029
Mestre TA, Sampaio C (2017) Huntington disease: linking pathogenesis to the development of experimental therapeutics. Curr Neurol Neurosci Rep 17(2):18. https://doi.org/10.1007/s11910-017-0711-8
Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Revi 3:CD006456. https://doi.org/10.1002/14651858.CD006456.pub2
Metman LV, Morris M, Farmer C, Gillespie M, Mosby K, Wuu J, Chase T (2002) Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59(5):694–699. https://doi.org/10.1212/wnl.59.5.694
Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Syst Rev 3:CD001447. https://doi.org/10.1002/14651858.CD001447.pub3
Mintz M (2023) Huntington’s disease: a systematic review and overview of treatments.
Miyazaki I, Asanuma M (2009) Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem Res 34(4):698–706. https://doi.org/10.1007/s11064-008-9843-1
Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther 25(1):12–23. https://doi.org/10.1016/j.ymthe.2016.11.010
Moon BB, Dahikar GD, Ganjiwale RO (2020) A Review on Huntington’s disease. Res J Pharm Technol 13(10):4990–4995. https://doi.org/10.5958/0974-360X.2020.00874.4
Morales E, Herrera C, Montaño L, Meza M, Del Villar N, Mendoza X, Rodríguez A (2022) Current knowledge and future directions in Huntington’s disease. Arch Neurocien 27(4):31–43. https://doi.org/10.31157/an.v1iinpress.346
Naia L, Ferreira IL, Cunha-Oliveira T, Duarte AI, Ribeiro M, Rosenstock TR, Laço MN, Ribeiro MJ, Oliveira CR, Saudou F, Humbert S, Rego AC (2015) Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington’s disease human lymphoblasts. Mol Neurobiol 51(1):331–348. https://doi.org/10.1007/s12035-014-8735-4
Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC (2016) Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides 58:73–81. https://doi.org/10.1016/j.npep.2016.01.009
Nemudryi AA, Valetdinova KR, Medvedev SP, Zakian SM (2014) TALEN and CRISPR/Cas genome editing systems: Tools of discovery. Acta Nat 6(3):19–40. https://doi.org/10.32607/20758251-2014-6-3-19-40
Nojadeh JN, Eryilmaz N, Ergüder Bİ (2023) CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI J. https://doi.org/10.17179/excli2023-6155
O’Suilleabhain P, Dewey RB Jr (2003) A randomized trial of amantadine in Huntington disease. Arch Neurol 60(7):996–998. https://doi.org/10.1001/archneur.60.7.996
Oh YM, Lee SW, Kim WK, Chen S, Church VA, Cates K, Yoo AS (2022) Age-related Huntington’s disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy. Nat Neurosci 25(11):1420–1433. https://doi.org/10.1038/s41593-022-01185-4
Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, Toyofuku T, Nakagawa Y, Kang S, Friedel RH, Sakoda S, Kikutani H, Kumanogoh A (2010) Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 184(3):1499–1506. https://doi.org/10.4049/jimmunol.0903302
Oosterloo M, Craufurd D, Nijsten H, van Duijn E (2019) Obsessive-compulsive and perseverative behaviors in Huntington’s disease. J Huntington’s Dis 8(1):1–7. https://doi.org/10.3233/JHD-180335
Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB, Investigators of the European Huntington’s Disease Network (2010) Observing Huntington’s disease: The European Huntington’s disease network’s REGISTRY. PLoS Curr 2:1184. https://doi.org/10.1371/currents.RRN1184
Owen NE, Barker RA, Voysey ZJ (2023) Sleep dysfunction in Huntington’s disease: impacts of current medications and prospects for treatment. J Huntington’s Dis 12(2):149–161. https://doi.org/10.3233/JHD-230567
Palaiogeorgou AM, Papakonstantinou E, Golfinopoulou R, Sigala M, Mitsis T, Papageorgiou L, Diakou I, Pierouli K, Dragoumani K, Spandidos DA, Bacopoulou F, Chrousos GP, Eliopoulos E, Vlachakis D (2023) Recent approaches on Huntington’s disease (Review). Biomed Rep 18(1):5. https://doi.org/10.3892/br.2022.1587
Paleacu D, Anca M, Giladi N (2002) Olanzapine in Huntington’s disease: olanzapine in Huntington’s disease. Acta Neurol Scand 105(6):441–444. https://doi.org/10.1034/j.1600-0404.2002.01197.x
Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2019) The role of microglia and astrocytes in Huntington’s disease. Front Mol Neurosci 12:258. https://doi.org/10.3389/fnmol.2019.00258
Pan L, Feigin A (2021) Huntington’s disease: new frontiers in therapeutics. Curr Neurol Neurosci Rep 21(3):10. https://doi.org/10.1007/s11910-021-01093-3
Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5(8):731–736. https://doi.org/10.1038/nn884
Pantiya P, Thonusin C, Chattipakorn N, Chattipakorn SC (2020) Mitochondrial abnormalities in neurodegenerative models and possible interventions: focus on Alzheimer’s disease, Parkinson’s disease. Huntington’s Dis Mitochondrion. https://doi.org/10.1016/j.mito.2020.08.003
Parkin GM, Corey-Bloom J (2023) Considerations and advances in Huntington’s disease clinical trial design. Biomarkers for Huntington’s disease: improving clinical outcomes. Springer, Cham, pp 405–431. https://doi.org/10.1007/978-3-031-32815-2_17
Parsons MP, Raymond LA (2023) Huntington disease. Neurobiology of brain disorders. Elsevier, Amsterdam, pp 275–292. https://doi.org/10.1016/B978-0-323-85654-6.00042-3
Paulsen JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow NR, Swenson MR (1995) Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology 45(5):951–956. https://doi.org/10.1212/wnl.45.5.951
Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL (2001) Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry 71(3):310–314. https://doi.org/10.1136/jnnp.71.3.310
Peña MS, Yaltho TC, Jankovic J (2011) Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 26(1):147–152. https://doi.org/10.1002/mds.23402
Pircs K, Petri R, Madsen S, Brattås PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Brückner M, Lundh SH, Petersén Å, Déglon N, Hébert SS, Parmar M, Barker RA, Jakobsson J (2018) Huntingtin aggregation impairs autophagy, leading to Argonaute-2 accumulation and global MicroRNA dysregulation. Cell Rep 24(6):1397–1406. https://doi.org/10.1016/j.celrep.2018.07.017
Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, Annett G, Torrest A, Deng P, Gutierrez J, Nacey C, Pepper K, Kalomoiris S, D Anderson J, McGee J, Gruenloh W, Fury B, Bauer G, Duffy A, Nolta JA (2016) Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington’s disease mouse models. Mol Ther 24(5):965–977. https://doi.org/10.1038/mt.2016.12
Priller J, Ecker D, Landwehrmeyer B, Craufurd D (2008) A Europe-wide assessment of current medication choices in Huntington’s disease. Mov Disord 23(12):1788. https://doi.org/10.1002/mds.22188
Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27(9):1083–1091. https://doi.org/10.1002/mds.25075
Quinn N, Marsden CD (1984) A double blind trial of sulpiride in Huntington’s disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 47(8):844–847. https://doi.org/10.1136/jnnp.47.8.844
Quintanilla RA, Johnson GVW (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull 80(4–5):242–247. https://doi.org/10.1016/j.brainresbull.2009.07.010
Rana T, Behl T, Sehgal A, Mehta V, Singh S, Bhatia S, Al-Harrasi A, Bungau S (2021) Exploring the role of autophagy dysfunction in neurodegenerative disorders. Mol Neurobiol 58(10):4886–4905. https://doi.org/10.1007/s12035-021-02472-0
Rascol O, Fabbri M, Poewe W (2021) Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol 20(12):1048–1056. https://doi.org/10.1016/S1474-4422(21)00249-0
Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW, Smeeth L (2016) The prevalence of Huntington’s disease. Neuroepidemiology 46(2):144–153. https://doi.org/10.1159/000443738
Reilmann R, Gordon MF, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Rynkowski G, Volkinshtein R, Savola J (2018) J05 Legato-hd study: a phase 2 study assessing the efficacy and safety of laquinimod as a treatment for Huntington disease. Clin Ther. https://doi.org/10.1136/jnnp-2018-EHDN.265
Reilmann R, Ross C, Testa C, Frank S, Evers M, De Haan M, Valles-Sanchez A, Konstantinova P, Van Deventer S, Higgins J (2020) Translation of AMT-130 preclinical data to inform the design of the first FDA-approved human AAV gene therapy clinical trial in adults with early manifest Huntington’s disease (4531). AAN Enterprises. https://doi.org/10.1212/WNL.94.15_supplement.4531
ReilmannR, Gordon MF, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Borowsky B, Rynkowski G (2019) The efficacy and safety results of laquinimod as a treatment for Huntington disease. In: AAN Enterprises. LEGATO-HD.https://doi.org/10.1212/WNL.92.15_supplement.S16.007
Reiner A, Dragatsis I, Dietrich P (2011) Genetics and neuropathology of Huntington’s disease. Int Rev Neurobiol 98:325–372. https://doi.org/10.1016/B978-0-12-381328-2.00014-6
Reveley MA, Dursun SM, Andrews H (1996) A comparative trial use of sulpiride and risperidone in Huntington’s disease: a pilot study. J Psychopharmacol 10(2):162–165. https://doi.org/10.1177/026988119601000213
Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC (2014) Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells. Free Radical Biol Med 74:129–144. https://doi.org/10.1016/j.freeradbiomed.2014.06.023
Richard A, Frank S (2019) Deutetrabenazine in the treatment of Huntington’s disease. Neurodegener Dis Manag 9(1):31–37. https://doi.org/10.2217/nmt-2018-0040
Rodrigues FB, Wild EJ (2018) Huntington’s disease clinical trials corner: February 2018. J Huntington’s Dis 7(1):89–98. https://doi.org/10.3233/JHD-189001
Rodríguez A, Morales E, Herrera C, Montaño L, Martínez K, Meza M, Del Villar N, Mendoza X (2022) Current knowledge and future directions in Huntington’s disease. Arch Neurosci. https://doi.org/10.31157/an.v1iinpress.346
Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther 12(4):618–633. https://doi.org/10.1016/j.ymthe.2005.05.006
Roos RA (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5:40. https://doi.org/10.1186/1750-1172-5-40
Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME (1999) Riluzole therapy in Huntington’s disease (HD). Mov Disord 14(2):326–330. https://doi.org/10.1002/1531-8257(199903)14:2%3c326::aid-mds1019%3e3.0.co;2-q
Rosenblatt A, Ranen NG, Nance MA, Paulsen JS (1999) A Physician’s guide to the management of Huntington’s disease. Huntington’s Disease Society of America, Arlington
Rosenstock T, Duarte A, Rego C (2010) Mitochondrial-associated metabolic changes and neurodegeneration in Huntington’s disease-from clinical features to the bench. Curr Drug Targets 11(10):1218–1236
Rosenstock TR, de Brito OM, Lombardi V, Louros S, Ribeiro M, Almeida S, Ferreira IL, Oliveira CR, Rego AC (2011) FK506 ameliorates cell death features in Huntington’s disease striatal cell models. Neurochem Int 59(5):600–609. https://doi.org/10.1016/j.neuint.2011.04.009
Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A (2002) Rivastigmine in the treatment of Huntington’s disease. European J Neurol 9(6):689–690. https://doi.org/10.1046/j.1468-1331.2002.00447_4.x
Roux PP, Barker PA (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67(3):203–233. https://doi.org/10.1016/s0301-0082(02)00016-3
Rui Y-N, Xu Z, Patel B, Chen Z, Chen D, Tito A, David G, Sun Y, Stimming EF, Bellen HJ, Cuervo AM, Zhang S (2015) Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol 17(3):262–275. https://doi.org/10.1038/ncb3101
Saft C, Burgunder J-M, Dose M, Jung HH, Katzenschlager R, Priller J, Nguyen HP, Reetz K, Reilmann R, Seppi K (2023) Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society). Neurol Res Pract 5:61. https://doi.org/10.1186/s42466-023-00285-1
Sajatouic M, Verbanac P, Ramirez LF, Meltzer HY (1991) Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington’s chorea. Neurology 41:156–156. https://doi.org/10.1212/wnl.41.1.156
Sampaio C, Borowsky B, Reilmann R (2014) Clinical trials in Huntington’s disease: interventions in early clinical development and newer methodological approaches. Mov Disord 29:1419–1428. https://doi.org/10.1002/mds.26021
Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc Natl Acad Sci 96:4604–4609
Schobel SA, (2021). Preliminary results from generation HD1, a phase III trial of tominersen in individuals with manifest HD. CHDI 16th annual HD therapeutics conference.
Seitz DP, Millson RC (2004) Quetiapine in the management of psychosis secondary to Huntington’s disease: a case report. Canadian J Psychiatry 49:413–413. https://doi.org/10.1177/070674370404900617
Seo H, Sonntag KC, Isacson O (2004) Generalized brain and skin proteasome inhibition in Huntington’s disease. Ann Neurol 56:319–328. https://doi.org/10.1002/ana.20207
Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK (2001) Riluzole in Huntington’s disease (HD): an open label study with one year follow up. J Neurol 248:866–869. https://doi.org/10.1007/s004150170071
Shannon KM (2020) Recent advances in the treatment of Huntington’s disease: targeting DNA and RNA. CNS Drugs 34:219–228
Sharma A, Behl T, Sharma L, Aelya L, Bungau S (2021) Mitochondrial dysfunction in Huntington’s disease: pathogenesis and therapeutic opportunities. Curr Drug Targets 22(14):1637–1667. https://doi.org/10.2174/1389450122666210224105945
Sharp AH, Loev SJ, Schilling G, Li S-H, Li X-J, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A (1995) Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron 14:1065–1074. https://doi.org/10.1016/0896-6273(95)90345-3
Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46:1584–1600. https://doi.org/10.1093/nar/gkx1239
Shin JW, Kim K-H, Chao MJ, Atwal RS, Gillis T, Macdonald ME, Gusella JF, Lee J-M (2016) Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet 25:4566–4576. https://doi.org/10.1093/hmg/ddw286
Shin JW, Hong EP, Park SS, Choi DE, Seong IS, Whittaker MN, Kleinstiver BP, Chen RZ, Lee J-M (2022) Allele-specific silencing of the gain-of-function mutation in Huntington’s disease using CRISPR/Cas9. JCI Insight. https://doi.org/10.1172/jci.insight.141042
Shirley M, Perry CM (2014) Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs 74:1097–1110. https://doi.org/10.1007/s40265-014-0231-7
Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y (2018) Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease. Sci Trans Med 10:eaar3959. https://doi.org/10.1126/scitranslmed.aar3959
Speidell A, Bin Abid N, Yano H (2023) Brain-derived neurotrophic factor dysregulation as an essential pathological feature in Huntington’s disease: mechanisms and potential therapeutics. Biomedicines 11:2275. https://doi.org/10.3390/biomedicines11082275
Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S (2001) Short-term effects of olanzapine in Huntington disease. Cogn Behav Neurol 14:69–72
Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, Frati L, Mansi L, Ciarmiello A (2009) Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 36:1113–1120. https://doi.org/10.1007/s00259-009-1103-3
Stahl CM, Feigin A (2020) Medical, surgical, and genetic treatment of Huntington disease. Neurol Clin 38:367–378. https://doi.org/10.1016/j.ncl.2020.01.010
Stimming EF, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D, Adams J, Beck C (2023) Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 22:494–504. https://doi.org/10.1016/S1474-4422(23)00127-8
Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA (2022) Huntington’s disease: diagnosis and management. Pract Neurol 22(1):32–41. https://doi.org/10.1136/practneurol-2021-003074
Sturrock A, Leavitt BR (2010) The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol 23:243–259. https://doi.org/10.1177/0891988710383573
Sugimoto T, Kuroda H, Horii Y, Moritake H, Tanaka T, Hattori S (2001) Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells. Jpn J Cancer Res 92:152–160. https://doi.org/10.1111/j.1349-7006.2001.tb01077.x
Tabrizi S, Cleeter M, Xuereb J, Taanman JW, Cooper J, Schapira A (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45:25–32. https://doi.org/10.1002/1531-8249(199901)45
Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin lowering strategies for disease modification in Huntington’s disease. Neuron 101:801–819. https://doi.org/10.1016/j.neuron.2019.01.039
Tabrizi SJ, Flower MD, Ross CA, Wild EJ (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16:529–546. https://doi.org/10.1038/s41582-020-0389-4
Terman A, Kurz T, Navratil M, Arriaga EA, Brunk UT (2010) Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial–lysosomal axis theory of aging. Antioxid Redox Signal 12:503–535. https://doi.org/10.1089/ars.2009.2598
Todi SV, Williams AJ, Paulson HL (2007) Polyglutamine disorders including huntington’s disease. Mol Neurol. https://doi.org/10.1016/B978-012369509-3.50019-6
Tong H, Yang T, Liu L, Li C, Sun Y, Jia Q, Qin Y, Chen L, Zhao X, Zhou G, Yan S, Li XJ, Li S (2023) Aberrant splicing of mutant huntingtin in Huntington’s disease knock-in pigs. Neurobiol Dis 187:106291. https://doi.org/10.1016/j.nbd.2023.106291
Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, Li. (2024) Huntington’s disease: complex pathogenesis and therapeutic strategies. Int J Mol Sci. https://doi.org/10.3390/ijms25073845
Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ (2017) Fifteen years of clinical trials in Huntington’s disease: a very low clinical drug development success rate. J Huntington’s Dis 6:157–163. https://doi.org/10.3233/JHD-170245
Valor LM (2023) Molecular research on Huntington’s disease. MDPI. https://doi.org/10.3390/ijms24054310
Van de Roovaart HJ, Nguyen N, Veenstra TD (2023ba) Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis. Pharmaceuticals 16(11):1513. https://doi.org/10.3390/ph16111513
Van de Roovaart HJ, Nguyen N, Veenstra TD (2023b) Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis. Pharmaceuticals (basel) 16(11):1513. https://doi.org/10.3390/ph16111513
van der Bent ML, Evers MM, Vallès A (2022) Emerging therapies for Huntington’s disease-Focus on N-terminal Huntingtin and Huntingtin exon 1. Biologics. https://doi.org/10.2147/BTT.S270657
Van Duijn E, Kingma E, Van Der Mast R (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441–448. https://doi.org/10.1176/jnp.2007.19.4.441
Van Vugt J, Siesling S, Vergeer M, Van Der Velde E, Roos R (1997a) Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 63:35–39. https://doi.org/10.1136/jnnp.63.1.35
Videnovic A (2013) Treatment of huntington disease. Curr Treat Options Neurol 15:424–438. https://doi.org/10.1007/s11940-013-0219-8
Vidoni C, Castiglioni A, Seca C, Secomandi E, Melone MA, Isidoro C (2016) Dopamine exacerbates mutant Huntingtin toxicity via oxidative-mediated inhibition of autophagy in SH-SY5Y neuroblastoma cells: beneficial effects of anti-oxidant therapeutics. Neurochem Int 101:132–143. https://doi.org/10.1016/j.neuint.2016.11.003
Walker FO (2007) Huntington’s disease. The Lancet 369:218–228. https://doi.org/10.1016/S0140-6736(07)60111-1
Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing Haplogroup. Am J Hum Genet 84:351–366. https://doi.org/10.1016/j.ajhg.2009.02.003
Watkins RE. News Releases News Releases.
Weihl CC (2013) Monitoring autophagy in the treatment of protein aggregate diseases: steps toward identifying autophagic biomarkers. Neurotherapeutics 10:383–390. https://doi.org/10.1007/s13311-013-0180-y
Wellington CL, Ellerby LM, Gutekunst C-A, Rogers D, Warby S, Graham RK, Loubser O, Van Raamsdonk J, Yang Y-Z, Gafni J (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington’s disease. J Neurosci 22:7862–7872. https://doi.org/10.1523/JNEUROSCI.22-18-07862.2002
Weydt P, Dupuis L, Petersen Å (2018) Thermoregulatory disorders in Huntington disease. Handb Clin Neurol 157:761–775. https://doi.org/10.1016/B978-0-444-64074-1.00047-1
Wiggins R, Feigin A (2021) Emerging therapeutics in Huntington’s disease. Exp Opin Emerg Drugs 26(3):295–302. https://doi.org/10.1080/14728214.2021.1962285
Wild EJ, Tabrizi SJ (2017) Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol 16:837–847. https://doi.org/10.1016/S1474-4422(17)30280-6
Wildridge B, Rozewicz S, Mohamed A, James J, Connolly G (2022) Use of clozapine for psychosis and chorea in Huntington’s disease systematic narrative review. Prog Neurol Psychiatry 26(2):38–43
Wokke J (1996) Riluzole. The Lancet 348:795–799. https://doi.org/10.1016/S0140-6736(96)03181-9
Wood H (2023) A new drug to treat chorea in Huntington disease. Nat Rev Neurol 19:387. https://doi.org/10.1038/s41582-023-00832-z
Wu Y, Lu J, Kang T (2016) Human single-stranded DNA binding proteins: guardians of genome stability. Acta Biochim Biophys Sin 48:671–677. https://doi.org/10.1093/abbs/gmw044
Wyant KJ, Ridder AJ, Dayalu P (2017) Huntington’s disease—update on treatments. Curr Neurol Neurosci Rep 17:1–11. https://doi.org/10.1007/s11910-017-0739-9
Xu X, Tay Y, Sim B, Yoon S-I, Huang Y, Ooi J, Utami KH, Ziaei A, Ng B, Radulescu C (2017) Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells. Stem Cell Reports 8:619–633. https://doi.org/10.1016/j.stemcr.2017.01.022
Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101:57–66. https://doi.org/10.1016/S0092-8674(00)80623-6
Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, Sun X, Qin Z, Jin P, Li S (2017) CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Investig 127:2719–2724. https://doi.org/10.1172/JCI92087
Yang H, Yang S, Jing L, Huang L, Chen L, Zhao X, Yang W, Pan Y, Yin P, Qin ZS, Tang B, Li S, Li X-J (2020) Author Correction: Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. Nat Commun 11(1):5989. https://doi.org/10.1038/s41467-020-19873-9
Yang Y, Yu D, Zhu X, Du G, Wang W, Zou F, Wang H, Zhang R, Ye L, Tian J (2021) Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. Eur J Med Chem 224(113718):113718. https://doi.org/10.1016/j.ejmech.2021.113718
Yin H, Kauffman KJ, Anderson DG (2017) Delivery technologies for genome editing. Nat Rev Drug Discov 16:387–399. https://doi.org/10.1038/s41573-023-00762-x
Zadegan SA, Kupcha L, Patino J, Rocha NP, Teixeira AL, Stimming EF (2023) Obsessive-compulsive and perseverative behaviors in Huntington’s disease. Behav Brain Res. https://doi.org/10.1016/j.bbr.2023.114767
Zadegan SA, Ramirez F, Reddy KS, Sahin O, Rocha NP, Teixeira AL, Furr SE (2024) Treatment of depression in Huntington’s disease: a systematic review. J Neuropsychiatry Clin Neurosci. https://doi.org/10.1176/appi.neuropsych.20230120
Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, Macdonald ME, Friedlander RM, Silani V, Hayden MR (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293:493–498. https://doi.org/10.1126/science.1059581
Acknowledgements
The authors extend their appreciation to the King Salman Center for Disability Research for funding this work through Research Group Number KSRG-2023-242.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Shafie, A., Ashour, A.A., Anwar, S. et al. Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease. Arch. Pharm. Res. (2024). https://doi.org/10.1007/s12272-024-01499-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12272-024-01499-w